These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10641779)

  • 1. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients.
    Johnson CA; Wakeen M; Taylor CA; Zimmerman SW; Burkart J; Bhattacharya A; Kosorok MR
    Perit Dial Int; 1999; 19(6):578-82. PubMed ID: 10641779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
    Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
    Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
    Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
    Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of once-weekly epoetin alfa.
    Barre P; Reichel H; Suranyi MG; Barth C
    Clin Nephrol; 2004 Dec; 62(6):440-8. PubMed ID: 15630903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R; Bhaduri S; Singh AK;
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
    Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
    Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
    McGowan T; Vaccaro NM; Beaver JS; Massarella J; Wolfson M
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1006-14. PubMed ID: 18417741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique.
    Taylor CA; Kosorok MR; Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1999 Oct; 34(4):657-62. PubMed ID: 10516346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
    Cheung W; Minton N; Gunawardena K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):411-8. PubMed ID: 11599659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
    Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.